Why the study?
Although the beta-3 adrenergic receptor is the least studied beta-adrenergic isotype, emerging literature indicates it is an appealing pharmacological target across metabolic, cardiovascular, urinary, and ocular diseases.
The beta-3 adrenergic receptor is emerging as a promising therapeutic target across multiple clinical areas, including cardiovascular and metabolic diseases.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Schena et al. (2019) conducted a review in Metabolic, cardiovascular, urinary, and ocular disease. β3-AR targeted therapies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: